Lupus Erythematosus: Cutaneous Manifestations and Treatment

Cutaneous lupus erythematosus (CLE) includes a broad range of dermatologic manifestations, which may or may not be associated with systemic manifestations. Specific CLE - defined by the presence of an interface dermatitis on histopathological evaluation - is divided into several sub-types, namely ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Francisca Alves (Author), Margarida Gonçalo (Author)
Format: Book
Published: Sociedade Portuguesa de Dermatologia e Venereologia, 2019-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_40e90eddb9ba465592ab7daef5d9cb4d
042 |a dc 
100 1 0 |a Francisca Alves  |e author 
700 1 0 |a Margarida Gonçalo  |e author 
245 0 0 |a Lupus Erythematosus: Cutaneous Manifestations and Treatment 
260 |b Sociedade Portuguesa de Dermatologia e Venereologia,   |c 2019-10-01T00:00:00Z. 
500 |a 10.29021/spdv.77.3.1118 
500 |a 2182-2395 
500 |a 2182-2409 
520 |a Cutaneous lupus erythematosus (CLE) includes a broad range of dermatologic manifestations, which may or may not be associated with systemic manifestations. Specific CLE - defined by the presence of an interface dermatitis on histopathological evaluation - is divided into several sub-types, namely acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), as well as other rarer forms such as LE profundus (LEP). Nonspecific skin findings, such as livedo reticularis or purpura are more frequently seen in patients with systemic disease. Diagnosis requires classification of the subtype, through a combination of physical examination, laboratory studies, histology and sometimes direct immunofluorescence, at the same time ensuring to exclude systemic disease. Regarding the treatment of CLE, antimalarials and topical steroids continue to be the standard of care; however, immunosuppressants, thalidomide analogs and monoclonal antibodies are possible systemic therapies for recalcitrant disease. Patient education on proper sun protection and avoidance of triggers is crucial. This paper reviews the clinical manifestations of CLE, as well as the treatment. 
546 |a EN 
546 |a PT 
690 |a Lupus Erythematosus, Cutaneous/complications 
690 |a Lupus Erythematosus, Cutaneous/diagnosis 
690 |a Lupus Erythematosus, Cutaneous/therapy 
690 |a Dermatology 
690 |a RL1-803 
690 |a Infectious and parasitic diseases 
690 |a RC109-216 
655 7 |a article  |2 local 
786 0 |n Revista da Sociedade Portuguesa de Dermatologia e Venereologia, Vol 77, Iss 3 (2019) 
787 0 |n https://revista.spdv.com.pt/index.php/spdv/article/view/1118 
787 0 |n https://doaj.org/toc/2182-2395 
787 0 |n https://doaj.org/toc/2182-2409 
856 4 1 |u https://doaj.org/article/40e90eddb9ba465592ab7daef5d9cb4d  |z Connect to this object online.